text:
More Videos...
Lightning vs 8.1l 2500HD
11.9* Lightning, meth and N2O vs 2500HD, 8.1l, N2O
'99 lightning vs. '04 Mach 1
lightning vs mach one
1999-2004 Ford F150 SVT Lightning-- Short Compilation
Just a short, rushed compilation of SVT Lightinings. If you see yours in the video, comment on it and let everyone know which truck it is! I do not claim ANY material in this video, all belong to respectful owners.
Ferrari F430, Audi S4
Ferrari F430, Audi S4


text:
Transocean (NYSE:RIG), one of the world's largest offshore drilling contractors, is expected to release its third quarter earnings on Monday, November 5. In the second quarter, the company reported a net loss despite strong sequential revenue and operating profit growth of 10% and 20%, respectively, due to certain non-recurring charges. For Q3, we expect the company to report a marginal decrease in revenues while earnings could also be hit due to non-cash charges relating to the sale of rigs.
Here are some of the factors we believe will influence the company's results for the quarter.
Deepwater Drilling
Transocean has been realigning its asset strategy to cater to the growing market for deepwater drilling given that it offers higher day rates and profit margins. During the quarter, the company took solid steps executing on the strategy as it announced the sale of 38 shallow water rigs to Shelf Drilling Holdings Limited for $1.08 billion last month.
- Transocean's 4Q'16 Earnings To Remain Weak As Contract Backlog And Dayrates Continue To Be Low
- How Sensitive Is Transocean's Enterprise Value To Its Capital Expenditure?
- Is Transocean Prepared For The Reversal In Commodity Prices?
- Transocean's Stock Surges As The Company Beats Earnings Estimates; But Contract Backlog Continues To Decline
- Transocean's Weak Dayrates And Utilization Weigh Heavily On Its 2Q'16 Earnings; Contract Backlog Continues To Drop
- Transocean To Witness A Notable Drop In Its 2Q'16 Earnings Due To Softness In Drilling Demand
Although the strategy is likely to have a positive long-term impact, the sale of the rigs is likely to result lower revenues and net profit margins for the quarter. Analysts have estimated that the selling price of the rigs was below the fair market value, and the company is expected to take a non-cash charge in Q3.
During the quarter, the company also reached a landmark $7.6 billion deal with Royal Dutch Shell to provide 4 new-build ultra-deepwater drill ships. The first drill ship is expected to be delivered in 2015. Ultra-deepwater rigs such as drillships and semi-submersibles can fetch day rates nearing $600,000 compared to shallow water rigs such as jackups that earn average rates of under $200,000 per day.
Focus on Efficiency
Transocean has steadily improved the revenue efficiency of its fleet to about 92.5% last quarter, up from 90% in Q1. Revenue efficiency is the actual revenue earned in a period divided by the highest potential revenue that could have been earned. Being in a capital intensive business, maintaining high utilization levels and revenue efficiency are critical to the company's success. Another factor that we will be watching is Transocean's control of its cost base through favorable contract terms and improved maintenance .
New Contracts and Rate Revisions
Renewed drilling activity in the Gulf of Mexico and contracts in growing offshore markets like Africa and Brazil should bode well for the company's earnings this quarter. Last quarter the company was awarded contracts for offshore rigs in Nigeria, Egypt and Gabon, with day rates higher by as much as 20% than previous rates. We believe these new contracts will be accretive to the company's earnings for Q3.
We will revisit our $57 price estimate for Transocean following the earnings release.
Understand How A Company's Products Impact Its Stock at Trefis

subset: commoncrawl


text:
- Hi there, welcome to Tribesmart. Log in to get started...
Subaru Impreza Wrx Full Day
Guide price: £380
Last updated on 18th Jul 2014
Tags: none
Subaru Impreza Wrx Full Day
The Subaru Impreza WRX, is a turbocharged version of the Subaru Impreza, an all-wheel drive automobile. The WRX has become a popular choice for automobile enthusiasts wherever it is sold for its performance and handling. Originally introduced in 1992 in Japan, then shortly afterwards in Australia and Europe, the WRX had a turbocharged flat-4 2.0L (then later a 2.5L), Subaru Boxer engine. Compared to the base Impreza, the WRX has wider low-profile tires, larger brakes, and firmer, higher quality suspension components.Get yourself behind the wheel of this impressive beast and feel the raw power distributed to the tyres through your right foot.
Login or Register to add this to your wish list or favourites.


text:
estevan rael-galvez
V.19 No.33 | 8/19/2010
Eric Williams ericwphoto.com
The Accidental Historian
Estevan Rael-Gálvez, executive director of the National Hispanic Cultural Center, on discourse and identity
By Joseph A. Baca
He was a terrible rancher. The son of a borreguero (sheep herder) in northern Taos County, Estevan Rael-Gálvez says he constantly lost his flock. Life on the farm wasn't for him. So with his mother's encouragement, he walked away from his family's generations-old trade of sheep and farming in Costilla and Questa to answer his calling—academia, and ultimately a much larger world where culture, art and politics converge. July marked Rael-Gálvez' first year as the executive director of the National Hispanic Cultural Center. Lively and cerebral, Rael-Gálvez has wasted no time in the influential seat, propelling the NHCC to the forefront of Hispanic cultural and political affairs both locally and nationally. One year into his service as head of this increasingly powerful institution, the Alibi invited Dr. Estevan Rael-Gálvez to answer our resolana-style questions (but more on that later).
NEWSLETTERS Great Alibi stories, events and deals delivered to your inbox each week. No fooling!
Today's Events
The Lady in Question at Vortex Theatre
Formal Cupping at Prosum RoastersMore Recommended Events ››
Kombat Kitty @ Stoneface • 3.4.2017
home | feature | news | film | music | art | food | classifieds | personals | staff | lo-fi | search
© 1996-2017 Weekly Alibi | firstname.lastname@example.com | Privacy Policy
View mobile version


text:
February LIVE Google Hangout ON AIR with Guest: Jeff Seder
Want to find the next Triple Crown winner? Tune in at 2 pm ET for 10 Questions LIVE to find out more!
Jeff Seder, turned his passion for champion thoroughbreds into a legal career. See how in the ABA Journal's 10 QUESTIONS article and continue the conversation by tuning in and submitting questions for 10 Questions LIVE!
About the Series
ABA's 10 Questions Live is a monthly conversation with innovative and non-traditional lawyers who have turned their passion into their practice and are following interesting, unexpected paths.


text:
My husband and I stayed at this charming Inn three nights, April 24 - 26, 2014. The location is excellent - just a short walk to the middle of 'town', good restaurants and LOTS of shops. Also can walk from the Inn to "Canyon Road," the site of many wonderful art galleries. The staff is outstanding - young, friendly, enthusiastic and extremely helpful. They went out of their way to see if they could help us with 'what to do' 'where to shop' and dining suggestions both before our arrival and during our stay. The Inn features Eastern Indian decor; seemingly a bit out of place for the area, but really quite lovely. Our room was large, well appointed, extremely clean and quiet. We had a microwave, coffee maker, teas, and a mini fridge stocked and re-stocked with little snacks and non-alcoholic beverages at no charge. The bed was large and extremely comfortable. We also had a lovely little fireplace that the staff offered to light for us every evening.The bathroom was amazing - huge, with a large soaking tub, and unique mosaic tiles which were gorgeous. We overlooked a lovely semi-private courtyard with a fountain, tables and lounge chairs. Climate control worked extremely well - TV featured all channels. In room Wi Fi worked well; reception for Verizon was great; AT&T not so much. The included breakfast, served in a charming small dining room in the Inn, was wonderful - good food, wide selection - and they will do pretty much whatever you want. Parking is plentiful - and they will park your car for you if you like. No one ever seemed to be asking for a tip - we inquired, and were told that everything was included, so gratuities were not expected. Thanks to the wonderful staff and Inn, our entire experience was serene - a relaxing and fun three days in a very interesting area - just what we wanted.
- Official Description (provided by the hotel):
- The Inn of the Five Graces combines luxury with an aura of mystery. With an ethnic décor enhanced by East Indian and Tibetan antiques, oriental carpets and nomadic textiles combined with Southwest architecture, the interiors feature many handcrafted pieces as well as spectacular tile mosaics. Passionate about this land with its wealth of Indian legends, the owners invite you to embark on a sensory voyage to fully savour this melting pot of cultures and colours. ... more less
- Reservation Options:
- TripAdvisor is proud to partner with Booking.com, Travelocity and Agoda so you can book your Inn of the Five Graces reservations with confidence. We help millions of travelers each month to find the perfect hotel for both vacation and business trips, always with the best discounts and special offers.
- Also Known As:
- Inn Of The Five Graces Hotel Santa Fe
- Inn Of The 5 Graces
- Hotel Of The Five Graces
- Of The Five Graces Hotel


text:
Submit News
Blog: Internet
Firefox 4 Won't Land Untill 2011
Shane McGlaun
October 28, 2010 11:16 AM
Recipient E-mail
Sender E-mail
Firefox 4 RC won't hit until 2011
New beta releases will continue
Firefox is one of the most popular browsers out there and Mozilla is always working on new features and upgrades for the browser. Fans of Firefox may have already tried out one of the
beta versions of Firefox 4
that have been posted for users to try out while waiting for the final version of the new browser to land next month.
Bad news has come from Mozilla with Mike Beltzner posting to the
group on Google Groups that the browser RC was being delayed until early 2011. However, new beta milestones will be released through December as bugs in the browser are fixed by the developers.
Beltzner points out that development is constant on Firefox 4 and progress is being made daily. The final launch date of Firefox 4 will come after the RC lands in early 2011. Beltzner wrote, "The frequent beta releases have been extremely helpful in identifying compatibility issues with existing web content, so we plan on continuing to release beta milestones through the end of December. Our estimate is now that release candidate builds will ship in early 2011, with a final release date close behind. Please note that, as always, this schedule is subject to change based on feedback from users and community members."
"What would I do? I'd shut it down and give the money back to the shareholders." -- Michael Dell, after being asked what to do with Apple Computer in 1997
Related Articles
Firefox 4 Beta 5 Hits, Gets Full GPU Support, HSTS, HTML5 Audio
September 8, 2010, 10:41 AM
Latest By Shane McGlaun
Windows Phone Sales Grow, But Market Share Continues to Lag Behind Competition
May 7, 2014, 9:39 AM
MSI Launches GS60 Ghost Pro 3K, GS70 Stealth Pro Gaming Notebooks
May 6, 2014, 12:00 PM
Apple to Launch Major Upgrade to Help Boost Sales Ahead of iPhone 6 Launch
May 6, 2014, 9:44 AM
Vermont Congressman Wants Federal EV Tax Credit Increased to $10,000
May 5, 2014, 8:37 AM
Eithad Airlines Offers the First Three-Room Suite on a Commercial Airliner
May 5, 2014, 8:13 AM
Report: AT&T Eyeing $40B DirecTV Purchase
May 1, 2014, 8:00 AM
Student Gmail Accounts No Longer Scanned for Targeted Ads
April 30, 2014, 10:31 AM
Samsung Galaxy K zoom Smartphone Gets Official, Offers 10x Optical Zoom
April 30, 2014, 9:53 AM
Google Autonomous Vehicles Are Working On Mastering City Street Driving
April 28, 2014, 10:25 AM
Samsung Reports that a Small Number of Galaxy S5 Smartphones Shipped with Broken Cameras
April 28, 2014, 10:00 AM
More Headlines
Latest Headlines
Science & Environment
February 20, 2017, 6:37 AM
The USA's newest weather satellite sends first photos.
January 24, 2017, 6:41 AM
Netflix took a decision to invest in original content
January 19, 2017, 7:00 AM
Amazon Airborne Fulfillment Center – Your Merchandise Drop-Shipped from the Clouds
December 29, 2016, 5:00 AM
Amazon is experimenting with a new kind of grocery stores, Amazon Go
December 8, 2016, 5:00 AM
Google has developed Deep Learning Algorithm to detect Diabetic Eye Disease
December 4, 2016, 5:00 AM
More Headlines
Most Popular Articles
Gigabit Are you looking for an Ultra Compact board?
February 22, 2017, 6:30 AM
Dell XPS 13 Touch – Rose Gold Edition
February 23, 2017, 7:29 AM
ASUS ROG Maximus IX - Among the Best of the Best
February 21, 2017, 7:50 AM
Comparison: Tag Heuer Connected Modular VS Samsung Gear S3
February 20, 2017, 7:20 AM
Xiaomi Mi Note 2 – This Chinese Phablet is the Best
February 24, 2017, 7:25 AM
Latest Blog Posts
Gaming News of The Day
Saimin Nidarson
Feb 28, 2017, 6:56 AM
How much Ram do you need for gaming?
Saimin Nidarson
Feb 27, 2017, 6:00 AM
Interesting News of the Day
Saimin Nidarson
Feb 25, 2017, 7:37 AM
AMD and More
Saimin Nidarson
Feb 24, 2017, 5:55 AM
Saimin Nidarson
Feb 23, 2017, 6:30 AM
Health News
Saimin Nidarson
Feb 21, 2017, 6:12 AM
Here is how startups are helping new parents in raising children
Saimin Nidarson
Feb 20, 2017, 6:45 AM
Around the World
Saimin Nidarson
Feb 18, 2017, 5:48 AM
News of Future
Saimin Nidarson
Feb 17, 2017, 6:30 AM
Amazon parachutes May Float Packages to Customers
Elroy Bethell
Feb 16, 2017, 8:00 AM
Now you Can Watch Facebook on Your TV
Elroy Bethell
Feb 15, 2017, 7:42 AM
Some News
Saimin Nidarson
Feb 14, 2017, 5:36 AM
Razer Blade Stealth – Little Kaby Lake Powerhouse
Elroy Bethell
Feb 13, 2017, 7:50 AM
Android 7.0 Nougat 7.0 Update Bring Less Battery Life for Samsung Galaxy S7 & S7 Edge
Elroy Bethell
Feb 12, 2017, 7:45 AM
Apple iPhone 8 – OLED Display & Wireless Charging
Elroy Bethell
Feb 11, 2017, 8:09 AM
What's New?
Saimin Nidarson
Feb 10, 2017, 6:15 AM
Unleashed News
Saimin Nidarson
Feb 9, 2017, 6:00 AM
Eye catching news
Saimin Nidarson
Feb 8, 2017, 6:16 AM
Some World News
Saimin Nidarson
Feb 7, 2017, 6:15 AM
Today's news
Saimin Nidarson
Feb 6, 2017, 10:11 AM
Some News
Saimin Nidarson
Feb 5, 2017, 7:27 AM
More Blog Posts
Copyright 2017 DailyTech LLC. -
RSS Feed
About Us
Terms, Conditions & Privacy Information
Kristopher Kubicki


text:
Podcast: DF #87: Going Rogue
By Kush 1 Comments
This week's "What We've Been Playing" features discussion on Rogue Warrior, Dante's Inferno, Silent Hill: Shattered Memories, LEGO Rock Band, Tekken 6, The Saboteur, WET, Puzzlegedon, Alien Breed Episode 1, Mushroom Wars, Topatoi, and plenty more. We follow that up with some gaming news and a bunch of crap that I don't know about as I had to leave extra early this week. We hope you enjoy the show and don't forget to rate/review us on iTunes.
- Site: Pixelated Sausage
- Podcast: DF #87: Going Rogue


text:
Let us know when your receive great advice so we can thank our lawyers and point others with similar questions in the right direction.Got it!
..helping support our son when he did have money.
Your "question" doesn't make sense. Whether or not he helped when he had money has nothing to do with the here and now.
Per your question, I am assuming that a child support order has been entered whereby your child's father is under a court order to provide support for your child. With that said, if he wanted to reduce or abate his child support obligation, he (not you) must file the motion. Moreover, should he file the motion, he must show the judge that a modification or abatement is justified since there has been a "change in circumstances" (i.e. he is locked up); however, please know that the judge shall ultimately consider all the factors and make a decision. Furthermore, the fact that a person paid support when he "did have money" has no effect on the motion to modify or abate.
if HE wants to modify his support obligation, HE (not you) must do so.
if you are receiving any public aid including link or all kids medical, then the support is not yours to decrease, it belongs to the state.
take all your child support papers to a lawyer for a consultation.
Post a free question on our public forum.Ask a Question
- or -
Search for lawyers by reviews and ratings.Find a Lawyer


text:
About Bag of Bees
We are a design studio based in Belfast, Northern Ireland formed by Barrie Holden and David Woods in 2011. Since then we have grown in size and capability, bringing together further experience in brand design, web design & graphic design.
In our studio, designers work directly with clients to get the best outcome from every job. We believe that working with a design team should be an overwhelmingly positive experience and our clients have responded by trusting us to deliver more and more of their requirements. They enjoy working with us because of our ability, enthusiasm and patience. And because we take the time to check.
We work for multinational companies and sole traders alike, across a broad spectrum of sectors. We take the time to get to know our clients, to understand their organisation and what they need and how best to talk to their customers. Ensuring they get the results they desire.
David Woods – Partner
David is a creative working primarily in branding and print design although being a partner means he has experience across all disciplines. David works directly with new and potential clients to introduce our work and way of working in order to build long-lasting partnerships.
Barrie Holden – Partner
Barrie is a partner in Bag of Bees with creative experience across digital and graphic design. He works with all our clients to make sure they are getting the quality and service they expect.
Sean Greer
Sean has a wealth of top-level experience in branding and brings this level of attention to detail to every job. Key recent projects include Risk & Resilience, Ortho Only and Wee ChoCo.
Ed Manson
Ed is a coder working with all our clients to get the most from their websites and email campaigns. Key recent projects include Films By Ben, Blick Studios and Lissanoure Castle.


text:
Generik Ltd
Our Mission
Using our experience, we provide solutions for IT systems' design and management.
We specialise in migrations from legacy infrastructure to cloud, development operations and infrastructure.
Our staff is at the fore front of DevOps and agile development. We provide guidance and implementation support for Micro Services infrastructure.


text:
Currently Accepting Training Resumes
This project received 2 bids from talented freelancers with an average bid price of $910 USD.Get free quotes for a project like this
Project Budget$250 - $750 USD
Total Bids2
Project Description
Currently Accepting Training Resumes (Instructional Designers, eLearning Developers, Project Managers, Trainers, Audio, Technical, etc.)
I am putting together a new site to help us as Training Consultants. It is called www.TrainingGig.com.
I know that we currently have to go to multiple sites to find our gigs, so I decided to set up a new website called TrainingGig.com. It matches Training Projects with Training Consultants. Right now, I am looking to beef it up with resumes from my personal contacts, groups, and freelancer sites (such as yourself ), so that I can work out the kinks. Once I get enough resumes on the site (most likely within the next week), I will be contacting prospective companies to post projects. Right now, there are some sponsored project links on the main page, and a couple of small projects that I was using as a test, but I will augmenting them with additional ones within the next week or two, so that you will be able to search for Training Projects. I get tons of job offers regularly via email, job groups, job boards, etc and I want to share them with my colleagues.
Would you be interested in posting your resume? And do you know of any other consultants that might want to as well? It is completely FREE! I will let you know once we start getting more targeted job leads.
Once you register, you can copy and paste your resume information into the various sections. In addition, once you publish your resume, there is an option from the My Dashboard section to upload a Word version of your resume as well. AND... you can link my website directly to your LinkedIn profile!
During this startup phase, if you notice any issues with the site, please let me know. I am working this in between my other projects, so an extra set of eyes would be awesome.
Skills Required
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
Predicting a local recurrence after breast-conserving therapy by gene expression profiling
DOI: 10.1186/bcr1614
© Nuyten et al.; licensee BioMed Central Ltd. 2006
Received: 11 April 2006
Accepted: 30 October 2006
Published: 30 October 2006
To tailor local treatment in breast cancer patients there is a need for predicting ipsilateral recurrences after breast-conserving therapy. After adequate treatment (excision with free margins and radiotherapy), young age and incompletely excised extensive intraductal component are predictors for local recurrence, but many local recurrences can still not be predicted. Here we have used gene expression profiling by microarray analysis to identify gene expression profiles that can help to predict local recurrence in individual patients.
By using previously established gene expression profiles with proven value in predicting metastasis-free and overall survival (wound-response signature, 70-gene prognosis profile and hypoxia-induced profile) and training towards an optimal prediction of local recurrences in a training series, we establish a classifier for local recurrence after breast-conserving therapy.
Validation of the different gene lists shows that the wound-response signature is able to separate patients with a high (29%) or low (5%) risk of a local recurrence at 10 years (sensitivity 87.5%, specificity 75%). In multivariable analysis the classifier is an independent predictor for local recurrence.
Our findings indicate that gene expression profiling can identify subgroups of patients at increased risk of developing a local recurrence after breast-conserving therapy.
Breast-conserving therapy (BCT) is a well-established treatment modality for early (stages I and II) breast cancer. The treatment consists of complete surgical excision of the tumor followed by whole breast irradiation. In multiple randomized trials comparing BCT with mastectomy, their equality in overall survival has been shown [1–7]. A large population-based Danish series showed that in different age categories (less than 35 years, 35 to 39 years, 40 to 44 years and 45 to 49 years) of young patients, survival was not negatively influenced by BCT [8]. However, local recurrence rates were significantly higher after BCT than after mastectomy in all series. The standard treatment for a local recurrence is a salvage mastectomy, which negates the original cosmetic intentions of BCT. More importantly, a recent meta-analysis by the Early Breast Cancer Trialists' Collaborative Group showed a negative impact of a local recurrence on survival [9]. They concluded: 'Differences in local treatment that substantially affect local recurrence rates would, in the hypothetical absence of any other causes of death, avoid about one breast cancer death over the next 15 years for every four local recurrences avoided, and should reduce 15-year overall mortality.'
Identifying patients at high risk for local recurrence in advance and individualizing treatment in these patients (for example, a higher radiotherapy dose ('boost') or a primary mastectomy) is desirable. Several risk factors for local recurrence have been recognized [10–17]. Margin status, young age, an incompletely excised extensive intraductal component and inadequate radiotherapy dose (boost) have been identified as important risk factors for local recurrence [18]. Adjuvant systemic treatment (chemotherapy or hormonal therapy) is known to reduce the risk of a local recurrence [12, 14, 16].
Previous studies have shown the ability to predict distant-metastasis-free and overall survival in breast cancer with the use of microarray analysis [19–25]. Mechanisms of recurrence in the breast are not necessarily the same as mechanisms involved in distant metastasis. Theoretically, radioresistance of the tumor cells would be an important factor in local recurrence after BCT but not necessarily in distant metastasis.
Previous analyses of gene expressions patterns in a series of 295 early-stage breast cancer patients have identified gene expression signatures that powerfully predict the risk of distant metastasis and mortality [22, 23, 26, 27]. In the present study we used a supervised approach to search for gene expression signatures that predict the risk of local recurrence after BCT in a series of 161 early-stage breast cancer patients.
Materials and methods
Tumor samples and patients
This analysis is based on previously reported gene expression profiles of tumors from a series of 295 stage I and II breast cancer patients treated at the Netherlands Cancer Institute between 1984 and 1995 [23]. All patients were under 53 years of age at the time of diagnosis. For this study all the patients from this series who received BCT (n = 161) were selected. BCT consisted of a wide local excision and axillary lymph node dissection followed by whole breast irradiation (median dose 50 Gy, range 50 to 54 Gy; the use of 6, 8 or 18 MV photons depending on breast diameter); 144 patients received a boost to a median dose of 15 Gy, 98 patients received a low boost (14 to 18 Gy), and 46 patients received a higher boost (20 to 26 Gy). The boost technique was delivered using 192I (iridium) implantation (88 patients), electrons (31 patients) or photons (25 patients). Pathological margins were assessed as free of tumor in 134 patients, focal involvement by invasive carcinoma only in 3 patients, focal involvement by ductal carcinoma in situ (DCIS) only in 5 patients, and focal involvement by both DCIS and invasive carcinoma in 4 patients; in 8 patients there was more than focal involvement of the margins by DCIS, or the degree of margin involvement could not be determined with certainty. For four patients there was invasive carcinoma at the margin, but the extent of involvement could not be determined with certainty, and for three patients this was the case for both invasive carcinoma and a DCIS component. Of all 27 patients with any extent of involved margins, 2 did not receive a boost, 6 received a low boost and 19 a high boost of radiotherapy. Follow-up assessment was at least yearly, including mammography. Seventeen patients developed a local recurrence; the resection margins of the primary tumor had been free of any tumor for 15 of these 17 patients. One patient who later developed a local recurrence had focal involvement of the resection margins with invasive carcinoma, and one patient had focal involvement with DCIS. The 10-year local-recurrence-free percentage was 85% (median follow-up for all patients was 7.7 years, and 8.5 years for alive patients).
On the basis of the microarray identification number, patients were alternately assigned to the training set (that is, developing a predictor of local recurrence) or to the validation set. This was done separately for locally recurring and locally tumor-free patients, thereby creating almost equal-sized sets with balancing for local recurrence.
Characteristics of patients in the training and validation series
No. of patients
Non-local recurrence
72 (89%)
72 (90%)
144 (89%)
Local recurrence
9 (11%)
8 (10%)
17 (11%)
Tumor size T1/T2
50/31 (62%/38%)
48/32 (60%/40%)
98/63 (61%/39%)
46/35 (57%/43%)
44/36 (55%/45%)
90/71 (56%/44%)
Grade I/II/III
22/26/33 (27%/32%/41%)
21/28/31 (26%/35%/39%)
43/54/64 (27%/33%/40%)
Age <40 years
62 (77%)
64 (80%)
Follow-up (years)
26 (32%)
23 (29%)
49 (30%)
28 (35%)
30 (38%)
58 (36%)
Hormonal therapy
10 (12%)
8 (10%)
18 (11%)
66/15 (81%/19%)
55/25 (69%/31%)
121/40 (75%/25%)
Median RT dose (Gy)
Median boost dose (Gy)
Boost, yes/no
70/11 (86%/16%)
74/6 (93%/7%)
144/17 (89%/11%)
Margins infiltrating carcinomaa
73, 4, 4 (90%, 5%, 5%)
72, 3, 5 (90%, 4%, 6%)
145, 7, 9 (90%, 4%, 6%)
Margins DCISb
25, 48, 3, 5 (31%, 59%, 4%, 6%)
27, 41, 7, 5 (34%, 51%, 9%, 6%)
52, 89, 10, 10 (33%, 55%, 6%, 6%)
Clinical characteristics by local recurrence versus non local recurrence
Non-local recurrence
Local recurrence
p a
No. of patients
Tumor size T1/T2
86/58 (67%/33%)
12/5 (71%/29%)
98/63 (61%/39%)
83/61 (58%/42%)
7/10 (41%/59%)
90/71 (56%/44%)
Grade I/II/III
41/47/56 (28%/33%/39%)
2/7/8 (12%/41%/47%)
43/54/64 (27/33/40%)
Age <40 years
28 (19%)
7 (41%)
Median follow-up (years)
40 (28%)
9 (53%)
49 (30%)
50 (35%)
8 (47%)
58 (36%)
Hormonal therapy
16 (11%)
2 (12%)
18 (11%)
109/35 (76%/24%)
12/5 (71%/29%)
121/40 (75%/25%)
Median RT dose (Gy)
Median boost dose (Gy)
Boost, yes/no
131/13 (91%/9%)
13/4 (76%/24%)
144/17 (89%/11%)
Margins infiltrating carcinomab
129, 6, 9 (90%, 4%, 6%)
16, 1, 0 (94%, 6%, 0%)
145, 7, 9 (90%, 4%, 6%)
Margins DCISc
49, 76, 9, 10 (34%, 53%, 6%, 7%)
3, 13, 1, 0 (18%, 76%, 6%, 0%)
52, 89, 10, 10 (33%, 55%, 6%, 6%)
Microarray procedures
RNA isolation, labeling of complementary RNA, and hybridization to 25,000-element oliogonucleotide microarrays, and measurement of expression ratios were performed as described previously [23].
The microarray data for analysis of the 70-gene prognosis profile were obtained with the use of the same 25,000-element oligonucleotide array; the correlation coefficient of the expression of these 70 genes with the good prognosis profile was calculated as reported previously [22]. The two other gene lists used are derived from Stanford cDNA arrays [30]. The correspondence between genes represented by Stanford cDNA microarrays and Rosetta/NKI oligonucleotide microarrays were established by using Unigene identifiers (build 158, release date 18 January 2003 for the wound signature, as this was the original mapping carried out for the validation of the wound signature [26]). The primary hypoxia analysis was performed at a later time. We used build 172, release date 17 July 2004 [27]. Because of the relatively small number of genes, probes on the Rosetta/NKI array that were mapped to the same unigene cluster were averaged.
The entire expression database for all 295 patients is publicly available online [28], as are the files containing the expression ratios for the specific experiments (70 genes (Additional file 2), hypoxia signature (Additional file 3) and wound signature (Additional file 4) [29].
Class prediction and gene selection de novo
The first method we used for predicting local recurrence is PAM (prediction analysis for microarrays): class prediction as described by Tibshirani and colleagues [31]. This method shifts the mean expression level of each gene (possibly after transformation) for each class (for example local recurrence) towards the overall mean expression level for all classes by a fixed standardized difference (shrunken centroids). The class for which the shrunken centroid most closely reaches the observed expression pattern of a certain patient by using a Pearson correlation is then the predicted class for that patient. For a given shrunken centroid only those genes for which the shrunken means still differ from the overall mean will contribute to the distance between centroids and any individual tumor sample's expression pattern. The standardized difference, and thereby the number of relevant genes, is chosen by minimizing the prediction error using 10-fold balanced, leave-10%-out cross-validation within the training set. The same method is then used to predict classes for new samples (validation set).
Gene set enrichment analysis
Subramanian and colleagues [32] have described a method that analyzes whether or not predefined gene sets (representing biological pathways) are coordinately and significantly upregulated or downregulated between samples that represent different biological or clinical entities [32]. The program corrects for multiple testing. We applied this method to our data set and analyzed gene set C2 ('functional gene set'). The software and gene set are available for download [33]. C2 represents 504 gene sets. Standard parameters were used for the analysis. The threshold for false discovery rate is 25% before a gene set is called significantly upregulated or downregulated.
Established gene expression profiles and methods of supervised analysis
- 1.
The wound-response gene expression signature is a characteristic pattern of expression of a set of genes that have been identified as being induced or repressed in response to bovine serum, a surrogate wound environment [30, 34]. This so-called 'core serum response' has shown to be a strong predictive factor for outcome in cancer (breast, head and neck, lung and gastric) using metastasis-free and overall survival as endpoints [26, 30]. It is important to realize that a particular pattern of expression of these genes, not just the genes themselves, predicts outcome.
- 2.
The 70-gene prognosis profile was originally trained to predict metastasis within 5 years ('poor prognosis' group), or no metastasis within 5 years ('good prognosis' group) [22].
- 3.
The hypoxia profile is a gene expression classifier from an in vitro experiment in which epithelial cells are exposed to hypoxia [27].
First, these gene expression profiles were used in their original form and tested for their value in predicting local recurrence after BCT in the complete set of 161 patients.
Second, we optimized these profiles by using the clinical data on local recurrence.
Using the training data set, we calculated for each of the three profiles the average pattern of expression of the genes that comprised each profile, for patients who developed a local recurrence (local recurrence profile or local recurrence centroid). For all patients in the training and validation set we then calculated the non-centralized Pearson correlation to each of the three average patterns of expression (local recurrence profile or local recurrence centroid). A correlation value between -1 and +1 is thereby derived for all patients and indicates the similarity in gene expression between an individual patient (tumor) and the average gene expression of tumors from patients in the training set who developed a local recurrence.
All patients who developed a local recurrence were considered; 16 patients developed a local recurrence as a first event and in 1 patient local recurrence occurred concurrently with distant metastases. Local-recurrence-free percentages were calculated with the Kaplan–Meier method (log-rank test for comparison). All Kaplan–Meier curves are available as supplementary data in Additional file 5. Comparison of categorical variables between groups was performed with a χ2 test. For the multivariable analysis we used a Cox regression model. All p values are two-sided. All correlations were calculated by the non-centralized Pearson method. For analysis we used Winstat® for Excel (R. Fitch Software, Staufen, Germany), SPSS 13.0® (SPSS Inc., Chicago, IL, USA) and Microsoft Excel® (Microsoft Corporation) were used. The PAM analysis was performed with version 1.2 (November 2003) [31, 35].
Additional material and methods are available described in Additional file 9.
In a previously reported series of 295 patients with stage I and II breast cancer diagnosed at age less than 53 years, 161 had been treated with BCT (the remaining 134 patients underwent modified radical mastectomy). Of these 161 patients, 17 developed a local recurrence. From the series of 161 patients, a training and validation set were selected as described in the Materials and methods section, distributing local recurrences equally. This resulted in a balanced distribution of year of treatment and major risk factors for local recurrence between the two groups as well (Table 1).
Training and validation series
Nine out of 81 patients in the training set had developed a local recurrence at a median interval of 6.2 years (range 1.0 to 10.8 years); the median follow-up time for the patients in the entire training set was 7.9 years. Six out of nine local recurrence patients had received a boost (five patients received 15 Gy, one patient 25 Gy).
In the validation set, 8 out of 80 patients had developed a local recurrence at a median interval of 3.72 years (range 1.2 to 8.4 years); the median follow-up time for all patients in the validation set was 7.6 years. Seven out of these eight patients had received a boost (three patients received 15 Gy, four patients 25 Gy).
Can a local recurrence classifier be identified by supervised classification using all genes?
We used the PAM algorithm with the training data set to search for gene expression profiles predictive of local recurrence, starting with a gene list that consisted of the top 5,000 most variably expressed genes with technically well-measured expression, represented by microarrays (out of 25,000). The performance of this approach, as evaluated by cross-validation, seemed to be poor: only 4 out of 9 local recurrences and 50 of the 72 non-local recurrences could be predicted accurately in the training set at this threshold (using a profile based on 684 genes). The use of fewer genes resulted in more accurate prediction for non-local-recurrence patients, but less accuracy for local-recurrence patients. In the validation series only 1 out of 8 local recurrences and 65 out of 72 non-local recurrences were predicted correctly (PAM analysis is provided in Additional files 6, 7, 8).
Using predefined gene sets based on biological processes: gene set enrichment analysis
We used the GSEA (gene set enrichment analysis) software to analyze whether or not gene sets defined on the basis of biological processes or pathways were significantly correlated with local recurrence. We first ran the analysis on the full probe set (more than 23,000). We than ran the analysis on the same selection of genes used for the PAM analysis (the top 5,000). Neither the full probe set nor the top 5,000 probe set revealed any gene set to be significantly upregulated or downregulated in samples from tumors that recurred locally, after correction for multiple testing.
Using previously identified gene expression signatures to predict local recurrence
We have previously shown that three distinct gene expression signatures can each be used to subdivide breast carcinomas into two groups that are associated, respectively, with good and poor distant-metastasis-free and overall survival: a '70-gene' prognosis profile [22, 23], a wound-response signature [26, 30] and a hypoxia-response signature [27]. We tested whether these three signatures were also associated with a difference in the risk of local recurrence. The 70-gene prognosis profile was originally trained to predict metastasis within 5 years ('poor prognosis' group) or no metastasis within 5 years ('good prognosis' group); in the current series of 161 patients, 97 patients had tumors with a poor prognosis profile and 64 patients had tumors with a good prognosis profile.
The wound-response signature was derived from an in vitro model for wound healing and can be used to classify tumors as having an 'activated wound-response signature' or a 'quiescent wound-response signature' [26, 30]. In this series of tumors, 380 (out of 459) genes from the wound-response signature were identified; 65 tumors had an activated wound-response signature and 96 tumors had a quiescent wound-response signature.
The hypoxia-response profile is a gene expression classifier derived from an ex vivo model in which epithelial cells are exposed to hypoxia [27]. In this series of tumors, 123 (out of 168) genes from the hypoxia-response signature were identified. On the basis of the expression of these hypoxia-associated genes, the breast carcinomas in this study could be assigned to 36 cases with a hypoxia-response signature and 125 with a non-hypoxia signature.
Of these three signatures, only the wound-response signature showed some evidence (p = 0.04; log-rank) of predicting local recurrence (13% versus 19% at 10 years for quiescent versus activated).
Building a classifier for local recurrence based on existing gene selections
Because the supervised approach using all genes (class prediction; PAM) failed and the previously identified gene expression signatures could not convincingly predict the risk of a local recurrence, we used genes from the original profiles and constructed a new classifier based on the relationship of their expression patterns to clinical outcome observed in our study (local recurrence or no local recurrence).
Each of these three signatures was originally defined for purposes other than the prediction of local recurrence, but we hypothesized that the optimization of each signature's pattern threshold by training on local recurrence data might improve their performance for this new purpose.
Seventy-gene prognosis profile
Applying the method described in the Materials and methods section, a correlation value of 0.2364 was calculated as a cutoff point for the 70-gene expression profile as a predictor of local recurrence, resulting in one misclassified patient with local recurrence. The recurrence risks at 10 years were 7% and 28% for the low-risk and high-risk groups, respectively.
In the validation set the separation could not be reproduced (p = 0.34; log-rank). The sensitivity was 63% (5 out of 8) and the specificity 50% (36 out of 72). At 10 years the recurrence risk was 13% versus 14% for the low-risk group versus the high-risk group. Furthermore, more than half the patients were assigned by this classifier to the high-risk group (41/80).
Hypoxia-response signature
For the hypoxia-response gene expression signature, the threshold that misses one patient with local recurrence seemed to be 0.254. In the training set the estimated 10-year recurrence risks for the low-risk and high-risk groups as determined by using this threshold were 10% and 19%, respectively. The performance of this signature on the validation set was not significant (p = 0.4). By employing this threshold on the validation set, 46 patients (58%) were classified as 'high risk' and 34 (42%) as low risk. At 10 years the recurrence risk was 13% versus 15% for low-risk versus high-risk, respectively. The sensitivity and specificity were 75% (6 out of 8) and 44% (32 out of 72), respectively.
Wound-response signature: core serum response genes
Performance of three different supervised analyses on validation series
WS supervised
70-genes supervised
Hypoxia supervised
Sensitivity (percentage)
Specificity (percentage)
Low risk/high riska (percentage)
10-year LC low/high (percentage)
p b
Cox regression: multivariable analysis
Cox regression analysis on local recurrence: clinical risk factors and wound signature (validation series only)
Risk factor
Hazard ratio for local recurrence
95% CI for hazard ratio
Age <40 years
Tumor size T2/T1
Boost treatment no/yes
Wound signature high risk/low risk
We have shown that gene expression profiling using DNA-microarray analysis can be used in risk stratification for local recurrence after BCT in breast cancer patients. We tested several different methods: standard supervised analysis (PAM and GSEA, with local recurrence as the end point), profiles that have previously been used to predict distant metastasis and survival, and a combination of both approaches by supervising these previously established predictive profiles with clinical data on local recurrence.
The supervised wound-response signature derived by this approach is the only profile that could predict a local recurrence after BCT. This new method begins with a biologically defined gene set and constructs a classifier by a supervised learning procedure from the expression pattern of the selected gene set, using clinical data. This thereby uses not only the genes themselves but also the expression levels for the different genes in the signature that are correlated with the clinical end point (local recurrence). The power of this signature in predicting local recurrence was highly significant, even if we conservatively take into account the fact that we tried a total of seven methods, by applying a Bonferroni correction to the p value of 0.0008 associated with the supervised wound signature. It is important to note that the gene set derived from an in vitro model, the wound response, but not the wound-response gene expression signature itself, was adapted to derive a gene expression pattern predictive of a local recurrence in patients who were treated with BCT.
Gene expression profiling has been successfully applied to distinguish molecular subtypes in breast cancer and to predict metastases and overall survival [19–23, 25]. More recently, gene expression profiling has also been used in trying to identify signatures predicting response to neo-adjuvant chemotherapy treatment [36, 37], and prognosis after treatment with tamoxifen [38–41]. Because many patients are suitable candidates for breast conservation on the basis of low baseline risk for developing a local recurrence, this treatment has become standard for more than 60% of breast cancer patients. A recently published pooled analysis shows that local recurrence is associated with an increased risk of developing distant metastases and subsequent death from breast cancer [42]. These findings are similar to the recently published EBCTCG (the Early Breast Cancer Trialists' Collaborative Group) meta-analysis [9]. After BCT without radiotherapy, an absolute increase of 5.4% in breast cancer mortality was seen. Moreover, local recurrence requires treatment (usually salvage mastectomy) and is associated with anxiety for affected patients. It is therefore important to tailor BCT in such a way that the risk of local recurrence is kept as low as possible, while optimizing the quality of life, including the cosmetic appearance of the breast. To select patients who are likely to benefit from BCT, clinico-pathological parameters are currently used to stratify patients by risk of local recurrence. These existing prognostic factors are far from perfect, and additional or better predictors of local recurrence would be of great potential benefit. Aggressive treatment including a larger excision volume and/or a higher local radiotherapy dose ('boost') significantly decreases the risk at of local recurrence but results in impaired cosmetic outcome [43]. In patients considered to be at low risk of local recurrence, the boost dose could be forgone and in patients with a high risk a boost should be administered or even escalated. Furthermore, for patients at very high risk of local recurrence a primary mastectomy can be offered.
Because the number of patients and the number of local recurrence events was low in this study, these results must be interpreted with caution. Although the hazard ratio for a local recurrence in the validation series is high (15), the confidence interval is wide (by univariate analysis, 95% CI 1.8 to 123). Given the potential contribution of this prognostic signature to improve decision making in planning the treatment of breast cancer and an improved understanding of the pathogenesis of local recurrence, an independent test of its predictive value is a high priority. Recently, in The Netherlands, a randomized clinical trial started, to compare the standard radiotherapy dose (50 Gy whole breast and 16 Gy boost to the tumor bed) with an additional boost dose (26 Gy). In this trial, fresh frozen tumor samples will be collected. This trial will allow prospective validation of the signature.
We have presented a method of integrating biologically derived gene expression profiles and clinical data to build a classifier for local recurrence after breast-conserving therapy. Although numbers of events are small and the resulting confidence intervals are wide, it is the first classifier based on microarray analysis to specifically predict a local recurrence after breast-conserving therapy. In our series the classifier is the most powerful predictor and is independent of clinical and pathological variables.
breast-conserving therapy
ductal carcinoma in situ
gene set enrichment analysis
prediction analysis for microarrays.
This work was supported by Dutch Cancer Society Grant NKB 2002-2575 (to DSAN, BK, HB and MJvdV), National Institutes of Health Grants CA77097 and CA85129 (to POB) and AR050007 (to HYC), and a National Science Foundation Predoctoral Fellowship (to JBS). POB is an Investigator of the Howard Hughes Medical Institute.
Authors' Affiliations
- Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, Rochard F, Le Chevalier T, Lacour J: Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol. 1989, 14: 177-184. 10.1016/0167-8140(89)90165-5.View ArticlePubMedGoogle Scholar
- Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, Mouridsen HT: Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr. 1992, 11: 19-25.Google Scholar
- Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, Salvadori B, Zucali R: Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001, 12: 997-1003. 10.1023/A:1011136326943.View ArticlePubMedGoogle Scholar
- Mariani L, Salvadori B, Marubini E, Conti AR, Rovini D, Cusumano F, Rosolin T, Andreola S, Zucali R, Rilke F, Veronesi U: Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer. 1998, 34: 1156-1162. 10.1016/S0959-8049(98)00137-3.View ArticlePubMedGoogle Scholar
- Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, del Vecchio M, Mariani L, Zurrida S, Rilke F: Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer. 1995, 31A: 1574-1579. 10.1016/0959-8049(95)00271-J.View ArticlePubMedGoogle Scholar
- van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der SE, Helle PA, van Zijl K, Bartelink H: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000, 92: 1143-1150. 10.1093/jnci/92.14.1143.View ArticlePubMedGoogle Scholar
- Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002, 347: 1233-1241. 10.1056/NEJMoa022152.View ArticlePubMedGoogle Scholar
- Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, Melbye M: Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer. 2004, 100: 688-693. 10.1002/cncr.20022.View ArticlePubMedGoogle Scholar
- Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 366: 2087-2106.View ArticlePubMedGoogle Scholar
- Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, van Tienhoven G, Andersen KW, Sylvester RJ, van Dongen JA: Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001, 19: 1688-1697.PubMedGoogle Scholar
- Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bartelink H: Risk factors in breast-conservation therapy. J Clin Oncol. 1994, 12: 653-660.PubMedGoogle Scholar
- Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, van de Vijver MJ: High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol. 2000, 18: 1075-1083.PubMedGoogle Scholar
- Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JW, van de Vijver MJ: Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys. 1999, 45: 73-83. 10.1016/S0360-3016(99)00158-3.View ArticlePubMedGoogle Scholar
- Fredriksson I, Liljegren G, Palm-Sjovall M, Arnesson LG, Emdin SO, Fornander T, Lindgren A, Nordgren H, Idvall I, Holmqvist M, et al: Risk factors for local recurrence after breast-conserving surgery. Br J Surg. 2003, 90: 1093-1102. 10.1002/bjs.4206.View ArticlePubMedGoogle Scholar
- Voogd AC, Peterse JL, Crommelin MA, Rutgers EJ, Botke G, Elkhuizen PH, van Geel AN, Hoekstra CJ, van Pel R, van de Vijver MJ, Coebergh JW: Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST). Eur J Cancer. 1999, 35: 1828-1837. 10.1016/S0959-8049(99)00220-8.View ArticlePubMedGoogle Scholar
- Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris J, Schnitt S: Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000, 18: 1668-1675.PubMedGoogle Scholar
- Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, et al: Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. Eur J Cancer. 2003, 39: 932-944. 10.1016/S0959-8049(03)00123-0.View ArticlePubMedGoogle Scholar
- Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, et al: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001, 345: 1378-1387. 10.1056/NEJMoa010874.View ArticlePubMedGoogle Scholar
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.View ArticlePubMedGoogle Scholar
- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.View ArticlePubMedPubMed CentralGoogle Scholar
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.View ArticlePubMedPubMed CentralGoogle Scholar
- van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.View ArticleGoogle Scholar
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.View ArticlePubMedGoogle Scholar
- Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003, 100: 10393-10398. 10.1073/pnas.1732912100.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.View ArticlePubMedGoogle Scholar
- Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005, 102: 3738-3743. 10.1073/pnas.0409462102.View ArticlePubMedPubMed CentralGoogle Scholar
- Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, et al: Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006, 3: e47-10.1371/journal.pmed.0030047.View ArticlePubMedPubMed CentralGoogle Scholar
- The van de Vijver Lab. [http://research.nki.nl/vandevijverlab/]
- Predicting a local recurrence after breast conserving therapy by gene expression profiling. [http://microarray-pubs.stanford.edu/wound_local_recurrence]
- Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, Rijn Mv M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2: E7-10.1371/journal.pbio.0020007.View ArticlePubMedPubMed CentralGoogle Scholar
- Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002, 99: 6567-6572. 10.1073/pnas.082099299.View ArticlePubMedPubMed CentralGoogle Scholar
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102: 15545-15550. 10.1073/pnas.0506580102.View ArticlePubMedPubMed CentralGoogle Scholar
- Gene Set Enrichment Analysis: overview. [http://www.broad.mit.edu/gsea/]
- Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, Trent JM, Staudt LM, Hudson J, Boguski MS, et al: The transcriptional program in the response of human fibroblasts to serum. Science. 1999, 283: 83-87. 10.1126/science.283.5398.83.View ArticlePubMedGoogle Scholar
- PAM: Prediction Analysis for Microarrays. [http://www-stat.stanford.edu/~tibs/PAM/index.html]
- Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004, 22: 2284-2293. 10.1200/JCO.2004.05.166.View ArticlePubMedGoogle Scholar
- Chang JC, Wooten E, Tsimelzon A, Hilsenbeck S, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness G, Allred DC, O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003, 362: 362-369. 10.1016/S0140-6736(03)14023-8.View ArticlePubMedGoogle Scholar
- Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, et al: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol. 2005, 23: 732-740. 10.1200/JCO.2005.05.145.View ArticlePubMedGoogle Scholar
- Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J: Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell. 2004, 5: 597-605. 10.1016/j.ccr.2004.05.016.View ArticlePubMedGoogle Scholar
- Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004, 5: 607-616. 10.1016/j.ccr.2004.05.015.View ArticlePubMedGoogle Scholar
- Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.View ArticlePubMedGoogle Scholar
- Vinh-Hung V, Verschraegen C: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004, 96: 115-121.View ArticlePubMedGoogle Scholar
- Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, et al: The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC 'boost versus no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys. 1999, 45: 677-685. 10.1016/S0360-3016(99)00211-4.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


text:
Union Presbyterian Church
656 State Route 380
Murrysville, PA 15668
Phone: 724 337-3042
Fax: 724 337-7758
Or use our contact form
Secretary Office Hours:
Tue/Thu from 9AM - 3PM
Pastor - Derek Campbell
Click Here for Directions
We welcome you to worship with us during these hours:
Sunday School:
Worship Service:
Welcome to Union Presbyterian Church's Web Site! We are glad that you are interested in Union Church and we hope that you will soon visit with us in person. We promise that if you do you will receive a warm welcome and an inspiring worship service!
Our web site is designed with multiple pages and links so that you can become better acquainted with us. But if you really want to get the flavor of our church and who we are, we invite you to join us for worship this Sunday at 11:00 AM (10:00 AM Memorial Day through Labor Day). But in the meantime, we hope that you spend time browsing through our web site to see who we are, what we are up to, and where you might get involved. May God richly bless you and those whom you love!
Click here to see all of our Stained Glass Windows
Derek Campbell: firstname.lastname@example.com
Pearl Jones: firstname.lastname@example.com
Lorraine Menk: email@example.com
Doreen Dailey: firstname.lastname@example.com
Deacons: firstname.lastname@example.com


text:
Evolution Sails New Zealand is owned by Rodney Keenan . The company forms part of the Evolution Group, an international, world class sail manufacturing, sail repair and service organization.
ENZ manufactures and services sails for superyachts, grand prix racing yachts, large cruising yachts and domestic racing and cruising yachts.
ENZ brings their world class sailing skills, leading edge design and quality-led innovation to ensure projects are secured with the international sector.
Evolution New Zealand has a worldwide reputation for focusing on their customers' needs – high performance quality sails and strong service support. ENZ is aware that its reputation for quality and service is paramount. Face-to-face visits with its clients enable them to have input into the design process. ENZ is driven by the passion to build the best sail, customizing each particular sail to the specific needs of the customer.
The Team - New Zealand
Director of ENZ, Rodney Keenan, is a sail maker and more often than not, a competitive yacht racer. His knowledge about the industry is deep as he regularly interacts with boat designers, boat owners and boat captains as the sales person and project developer and attends relevant trade shows.
Fellow Director, Graeme Robbins is also a sail maker and yacht racer. He is responsible for sail designs and operations as well as the international fitting and servicing of superyacht sails, which are manufactured in New Zealand. Graeme's passions are sail design, attention to detail and service.
Both Rodney and Graeme travel overseas regularly to service clients, sail in international regattas, and fit, service and maintain sails.
Rodney and Graeme between them have forty five years sailmaking experience. They are complemented by their team of world class sail makers who are passionate sailors themselves. Their experiences span Amercia's Cup, Volvo Round the World and Olympic Games campaigns. ENZ operates from a purpose built sail making facility in Auckland, City of Sails.
Start at the beginning with premium sail design and finish with great service!
61 Keeling Road, Henderson, Auckland, 0610, New Zealand
(Down Drive On Right)
Loft Location - New Zealand
61 Keeling Road
(Down Drive on Right)
Auckland, 0610,New Zealand
Phone: +64 9 836 5760
Phone: +64 9 838 1482
Fax: +64 9 336 1347
Contact: Rodney Keenan
Email: email@example.com
Mobile: +64 2 148 6135
Contact: Graeme Robbins
Email: email@example.com
Mobile: +64 2 155 6556


text:
Ryan Boatright returning to UConn for senior season
Per multiple reports late Friday afternoon, UConn junior shooting guard Ryan Boatright will return for his senior season.
Boatright averaged 12.1 points, 3.5 rebounds and 3.4 assists last season for the national champion Huskies. He and senior Shabazz Napier blended into a powerful, dynamic tandem that gave the Huskies a memorable, unprecedented run, becoming the first No. 7 seed to win it all.
But with no guarantee of being drafted, Boatright has opted to do what Napier did a year ago: bypass the NBA Draft and return for a fourth year of college basketball. He'll be the leading option in scoring for the Huskies, who will be a top-20 preseason team.
"I couldn't be happier that Ryan will be back with us next season," UConn coach Kevin Ollie said in a statement. "Not only for his terrific basketball talents, but to provide tremendous senior leadership for us, both on and off the court. The growth and maturity he has shown throughout his career has been wonderful and I expect that to continue as he works toward his degree."
Boatright's teammate, junior DeAndre Daniels, announced earlier on Friday that he would leave school and pursue the NBA. Daniels' stock took a big jump in the final five weeks of the season, and he could break through to the late first round.
UConn will also have Amida Brimah next season, but Brimah underwent left-shoulder surgery on Friday, and he'll be out 4-5 months.


text:
[PHP+Juery+MySQL+Bootstrap] Several new functions in website
- Status Closed
- Budget $8 - $15 USD / hour
- Total Bids 34
Project Description
Im looking for 5-6 php coders who will work in next days/weeks
over business application project.
I need exactly up to 5 coders and one project manager who will manage all tasks completion.
Software will help marketer and entrepreneurs to create automated sales pages, shop etc.
At the moment we have over 40 function needed to be applied to our user panel (like in attached file)
You need to know php, jquery, bootstrap, smarty, mysql to implement specified functions.
Let me know how many hours per day you're able to work. Show me also your porftolio.
If you will be chosen, i will set schedule to all coders to show you more details on live training (structure of code, of files and what you have to do)
You will work with SVN with other coder and you need to daily raport progress of your function/task to manager.
Also you will have to communicate with other coders to accomplish specified tab you will get to code.
Specify in your offer would you be just coder or coder+manager.
Ps. I prefer coders who can work minimum 80% of your all time on my project.
If you have lot of project you are doing right now and it will be your additional job, please dont put your offer here (its better to focus on 1-2 projects than on 10)
Firms with already set group of coders are welcome.Get free quotes for a project like this
Skills Required
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
It is said that dwarves have problems with using magic (maybe they cannot cast spells at all). This is an attempt to create a distinctly dwarwen school of magic. The way you use it is of course yours.
Did you, like me, sit in the cinema thinking "Now this is what I want to achieve for my campaign climax"? Did you sit around afterwords trying to figure out how? Well I did, and here it is.
Taverns are the love of my life. This post is a compendium of around 100 tavern names, from fine dining to coarse fighting, to use in your campaign or world.
Every kind of gamer has the dark potential to disrupt the game if they take their natural interests to extremes. Roleplaying, taken to extremes, can destroy a campaign for a troupe just as easily as any power gamer, rules lawyer, or munchkin.
A very short piece
Although it can be a distraction, it can also add atmosphere to an adventure to have music playing in the background. Here are some pieces I'd recommend for different situations.
The eyes of the all seeing are never ending. The truth can only be revealed to those willing to bear the burden.
His eyes opened in disbelief, the battered spectacles rising slightly on his brow. To everyone around him, everything was normal. As it should be. To his eyes, the light was nearly unbearable. An aura of energy filled his vision completely. He knew what it was he saw, what the others could not. He knew he saw the impossible, and he wanted it all for himself.
As a way of defining your character better
But, O Fellow Denizens of the Citadel, I ask this - what other kinds of unique elements can you come up with?
An influential fungus among us!
Cheza Betaze is the 17th Nekron urban area found in the Northern Cascades. The reasons why it is the best known of all Nekron cavern cities is that is has an easily accessible surface entrance/ exit which is just off the main Cascade trade trails. Being of recent construction in a time of prosperity, it is a city the Nekron feel proud off.
You should feel proud today, knowing that you will be the reason why another person will live. Why they will escape the brink of death and be able to heal all injuries. This is a great thing and you should feel elation knowing because of you, they will live. Unfortunately you must die for them to live; such is the way of the world.
-Inganno - Follower of Caedmon, Alchemist of Shadow
The unearthly sound echoed across the faire over the din of the crowd. An apprentice trying to make some extra coin had found a way to utilize his training tool. While this would scandalize his master and his peers, the common folk were mesmerized by the unique sound this instrument performed.
To give a world a feeling of otherworldliness, it is best to replace some standard, everyday objects by imaginitive replacements. I thought I'd turn to musical instruments as music often defines (or embodies) a culture.
This is just a first idea, feel free to post some more, because I will…
Settled two hundred years before, the people were fleeing war and tyranny. Establishing a comfortable existence in the fertile, but empty valleys, they soon learned who the lands belong to. A mighty dragon called only Death, came and burned the city to the ground, and later again, and again, sending with fire also his (hers?) evil laughter and shouts of pleasure at the destruction. The survivors did not wish to leave, and decided for a new strategy.
Nestled between a plateu and a river that soon leads to the sea, is the Elventi city of Anshenestardaywadaden or more literally Place Between Sunset and Falls. This city has no purpose other than being beautiful. Anshenestardaywadaden is a riot of color, between Elventi magics and the near tropical climate, there are hundreds of beautiful flowers here. It is best known as a place of waiting for another perfect sunset.
Every city (or town or village) expresses its personality (or the cultural personality of its people) and its identity through its buildings, roads, and other pieces of engineering. They are permanent expressions of the local culture.
Some cities have more spirit than others.
Although the stink and slime of the swamp is not the perfect habitat for dry plants, within forests of the Mura Katur can be found a respectable variety of lichens, mosses, and ground covers.
From the Black Marsh to the Glowing Swamps of Luminiall, the Mura Katur is home to a great abundance of funghi. Enclosed is a sampling of the many species found in its dank mires and soaked forests.


text:
Posted by anna on Tuesday, November 9, 2010 at 3:57pm.
number cells=total volume/cellvolume=3^3/1^3=27
if each side doubles, volume is now 2^3*27
The area of a cube can be found by AxBxC. Your cube is 27cm cubed. 27 of the little cells will fit in the cube.
Deez Nuts is your answer
Answer to first Question: 27 cells
Answer to Second Question: 126 cells
b/c 1st : 3*3*3=27
b/c 2nd : 2*3*2*3*2*3= 6*6*6= 126
Sorry... It 216 for the second question....... ¤Ð¤Ð


text:
- 1 correct something to make something right or accurate, for example by changing it or removing mistakes Read through your work and correct any mistakes that you find. Their eyesight can be corrected in just a few minutes by the use of a laser. They issued a statement correcting the one they had made earlier.
- 2 correct something (of a teacher) to mark the mistakes in a piece of work (and sometimes give a mark/grade to the work) I spent all evening correcting essays.
- 3to tell somebody that they have made a mistake correct somebody Correct me if I'm wrong, but isn't this last year's brochure? Yes, you're right—I stand corrected (= I accept that I made a mistake). correct (somebody) + speech 'It's Yates, not Wates,' she corrected him. Express YourselfCorrecting yourselfWhen you say something that was not quite what you intended, you can correct yourself in various ways: I'll be there at five fifteen, I mean five fifty—ten to six. It'll be Tuesday—sorry, I meant to say Thursday. Sorry, what I mean is, we need two handouts per person. We can meet in the conference centre—or rather in front of the centre. The painter—or should I say, the sculptor—was born in Padua. It's one t and double s—no, sorry, one s and double t. It's on the fifth floor—no, actually, it's the fourth. Can I get two lattes and an espresso—no, scratch that, three lattes. (North American English, informal) Word Origin Middle English (as a verb): from Latin correct-
verbjump to other results
BrE BrE//kəˈrekt//; NAmE NAmE//kəˈrekt//Verb Forms present simple I / you / we / they correct
BrE BrE//kəˈrekt//; NAmE NAmE//kəˈrekt//he / she / it corrects
BrE BrE//kəˈrekts//; NAmE NAmE//kəˈrekts//past simple corrected
BrE BrE//kəˈrektɪd//; NAmE NAmE//kəˈrektɪd//past participle corrected
BrE BrE//kəˈrektɪd//; NAmE NAmE//kəˈrektɪd//-ing form correcting
BrE BrE//kəˈrektɪŋ//; NAmE NAmE//kəˈrektɪŋ//
Check pronunciation: correct


text:
Download document:
Court of Appeal upholds Mr Ablyazov's right to continue to fund defence of claims - .PDF file.
In an important decision for Mukhtar Ablyazov and all individuals whose assets are subject to a freezing order, Lord Justices Beatson, Rimer and Floyd unanimously decided that a freezing order that prevents Ablyazov from disposing of, dealing with or otherwise diminishing the value of his assets other than in the ordinary and proper course of his business did not extend to preventing him from borrowing money to fund his legal expenses.
Ablyazov has, and continues to, fund his defence of the litigation brought against him by BTA Bank through loans provided by third parties. In an attempt to cut off Ablyazov's funding of his defence, thereby potentially depriving him of the ability to continue to defend himself, the bank applied for a declaration that Ablyazov's rights under the loans were assets for the purposes of the freezing order. The bank also applied in the alternative for Ablyazov to give disclosure of all of the drawings made under the loans. Unsurprisingly, the bank's application, which would have resulted in the overturning of established case law that has stood unchallenged for more than 10 years, was dismissed by Mr Justice Christopher Clarke in its entirety at first instance…
If you are registered and logged in to the site, click on the link below to read the rest of the Addleshaw Goddard briefing. If not, please register or sign in with your details below.


text:
- QLD - Brisbane
Darling Downs Zoo
Be AMAZED at our vast array of beautiful and ugly, dangerous and gentle, big and small, but always fascinating, wildlife and all just a short drive from Toowomba or Warwick.
Take a walk and get up close and personal with a number of our animals - Photo opportunities abound!
- Meet some Movie Stars
- Pose with a Python
- Learn about Lions
- Marvel at our Marmosets and
- Shiver at our Snake and Reptile Show
And that's just for starters!
Bring the family for a fabulous fun day.
More fun outdoor events in QLD!
Don't forget to Add Your Own Event and let everyone know about it!
- Time:
- Wed - Mon 9am to 4pm (last entry 3pm)
- Location:
- Darling Downs Zoo, Cnr of Gatton-Clifton Rd & Baines Rd, PILTON Map it
- Ages:
- All Ages / Family
- Cost:
- Please see details
- Event Info:
- Open every day during the school holidays!
Visit Website


text:
Well another longer than expected project, but one I am very pleased to present to you today. Here is Competitor Rival 107! As you can tell by the name, I used dimensions of the AR pistol MK 107 which was displayed on the front cover of a gun magazine on my store. At first I thought the concept of an AR pistol was a real life version of an oxymoron, but after a while of reading and thought I liked the idea. As the magazine came down off the sales floor, I began building. This gun is finished and ready for k'nex war 2013 with a large white rod magazine, a flip up red dot sight, and a nice range of at least 40 feet. I love this gun and I hope you will too here is the stats that the majority of you will read.
Great range over 40ft.
Good looks in my opinion
New magazine with internal mag pusher and a easy load slide
Flip up red dot sight
Lots of tatical rail length
Trigger guard and a strong trigger mechanism
Barrel does not look the best. Built for function.
white rods act like blue rods. Some shoot well, others don't you know how that goes.
You tell me. Something I need to work on? Comment about it.
Thanks for viewing! Ible' coming before the contest ends so please vote for my entries: Rockem Sockem Robots, Zip, and Shift!
<Update> Some internal pictures or the gun and some band placement pics>


text:
Top Definition
A program developed for ultimate success in a classroom setting; the program involves dressing up in slutty (but not scandalous) clothing during the first several class sessions. The purpose of dressing in such a way is so that the teacher or professor develops a low standard for his or her new student (we all know that slutty girls are viewed as dumb girls). However, when the first exam or test of intelligence rolls around, the student performs in a manner much higher than the teacher or professor expects. This occurs because the student dressing in a slutty manner is actually a decently intelligent person; however, the teacher or professor is mislead by her appearance, and therefore holds a low standard. This low standard is easily exceeded simply by performing in an average manner academically.
School is starting next week; let's go shopping for our slut for success outfits!
by slutacular August 17, 2011
The Urban Dictionary Mug
One side has the word, one side has the definition. Microwave and dishwasher safe. Lotsa space for your liquids.Buy the mug
The Urban Dictionary T-Shirt
Smooth, soft, slim fit American Apparel shirt. Custom printed. 100% fine jersey cotton, except for heather grey (90% cotton).Buy the t-shirt


text:
[PHOTO] Pseudocoris: Kentucky Frost | Tue, 4 Jan 2000 11:01:06" />
Hi ,
The last pseudocoris photo I sent, I got so excited, I forgot to sign my
name. I am Annette Milch from Lexington, Kentucky, zone 5/6.
Here is another pseudocoris seedling left here by Mark Cook when he
moved to Florida. It is growing next to Kentucky Moonbeam. This one's name is
Kentucky Frost and it is also registered in 1995 by Mark Cook but not
introduced to my knowledge.
Here goes.
Annette Milch Lexington, KY , USA Zone 5/6 email@example.com


text:
Click to Call
Dumpster Removal
Service Area
Contact Us
Dumpster Rental in Glenview, IL
If you are looking for a premier dumpster rental company in Glenview, IL you can dial 888-264-6660
to gather plenty of information about how Deliver My Dumpster can serve you. For a number of years, our company has been the company that Glenview homeowners call for trustworthy rentals and incredible customer service.
Our team is polite and well-trained, and our
roll off dumpster
are always top rated so that we are able to uphold our commitment to excellence. If you've never rented a dumpster in the past, give Deliver My Dumpster a ring so we can provide you with more help and advice. We will be more than willing to talk to you about the details of your undertaking and help you find the ideal model based on your requirements. It isn't necessarily easy to track down reasonable
rates. If you're looking for the best prices in Illinois, give Deliver My Dumpster a phone call. We will give you a list of services and charges so you understand exactly what you will be paying for. We don't believe in surprising our customers with additional or unwanted prices. We will give you all of the information up front regarding what you can expect, to help you plan your project successfully.
Various Types of Rental Units
In order to meet the requirements associated with the many different tasks that
happen to be used for in Glenview, several types of different styles available.
Portable models which are ideal for small cleanups
Mid-sized dumpsters for normal building
Commercial-sized units that are frequently recommended for demolition projects and larger construction applications
Deliver My Dumpster makes it really easy for Illinois residents to find
dumpster rental companies
they really need by offering all three sizes. It's important to notice that the dimensions represent the total square footage of the unit, not an overall length or width measurement. So, for example, a small 10 foot rental would be 10 square feet of storage area, not a 10×10.
Obtaining a Quote
Be ready with the following details when you contact Deliver My Dumpster for a quote.
The place where you need the rental dumpster, accompanied by your contact details
What sort of unit you'll need
The types of debris you need to eliminate
Other important points that are likely to help us meet your specifications more effectively
We are able to make it easier to understand any Illinois ordinances on debris removal that may possibly apply to your project. The more Deliver My Dumpster understands about what you require the
roll off containers
for, the easier it will be for us to give you guidance and accurate pricing for the services you are likely to require. Your contractor will give you more insight if you're not sure. You should call Deliver My Dumpster at 888-264-6660
if you have questions relating to our services or when you're all set to rent a dumpster. We serve all of Glenview, IL.
Which Items Are Not Permitted In the Dumpster?
Hiring a dumpster in Glenview carries with it some accountability . Many items usually linked with remodeling jobs are not allowed to be thrown away in your rented unit . Glenview has explicit regulations regarding unsafe items, to be sure they are disposed of correctly . Deliver my Dumpster at 888-264-6660
can provide you with all the guidelines about the rules pertaining to what is permitted to be thrown in the unit .
Dumpster rental Corsica
is another location that we service thus don't forget to find out more about our other top notch cities. It is possible more limitations apply in Glenview, IL, which may not apply in other states. Certain areas of the city may be prone to tighter rules depending on their environmental standing. It is important to notify Deliver my Dumpster where the work will be located so we can notify you of any relevant rules which could apply before the unit is provided .
Glenview Guidelines For The Disposal of Unsafe Items
Glenview prohibits citizens from putting any dangerous materials into a dumpster that may lead to injury or illness.
Paint and paint products such as turpentine
Large batteries
Chemicals such as gasoline, cleaning solutions, or fluorescent materials
Ammunition or items in danger of exploding
Anything that could contain asbestos
If any restricted materials are discovered in the dumpster, regardless of who disposed of them, you might be fined. Glenview might have other rules about hazardous items that can be on your construction site, so consult with the contractor to make sure your plans comply with the rules. If you are not allowed to dispose of certain materials in the dumpster , enquire what is necessary in order to dispose of it lawfully.
Restricted Over Sized Materials
There are restrictions banning certain oversized items from being placed in dumpsters in Illinois.
Giant home appliances like stove tops or refrigerators
Mattresses or box springs
Railroad Ties
Heavy building materials like brick
Check with Glenview officials about what might be prohibited for legal or health reasons. If you are uncertain about whether or not an item is banned, enquire before you dump it in the roll-off container . Anything that will make it too weighty for Deliver my Dumpster to drive away with your unit is not allowed as well, so keep those sorts of restrictions in mind.
Further Prohibited Items
Illinois enforces limitations on these and similar items , it is therefore prudent to be sure you establish exactly what is allowed in your area before tossing things away.
Smaller appliances like tv sets or computer systems
House cleaning chemicals
Construction materials such as sheetrock
Illinois have comprehensive listings of which items have to be disposed of in a careful way . Make sure you have a duplicate of the guidelines before commencing work on the construction site , so you are aware what can and cannot be thrown in the leased dumpster. Otherwise you may find yourself digging things back out to prevent fines. If you require further information or have any questions about dumpster leasing in Illinois, contact Deliver my Dumpster on 888-264-6660
. To acquire more information, find out more about a lot of our locations:
Kersey, PA dumpster rental
Map of Glenview:
Local Business Listings
Top Cities in Illinois
Chicago, IL
Rockford, IL
Naperville, IL
Peoria, IL
Bloomington, IL
Aurora, IL
Geneva, IL
Springfield, IL
Elgin, IL
Plainfield, IL
Barrington, IL
Champaign, IL
Lake Forest, IL
Schaumburg, IL
Joliet, IL
> Dumpster Rental in Glenview, IL
Cities Near Glenview
Grayslake, IL
Gurnee, IL
Harvard, IL
Highland Park, IL
Highwood, IL
Ingleside, IL
Island Lake, IL
Lake Bluff, IL
Lake Forest, IL
Lake Villa, IL
Zip Codes Near Glenview, IL
60004 60005 60006 60007 60008 60009 60015 60016 60017 60018 60019 60022 60025 60026 60029 60035 60037 60038 60040 60043 60044 60045 60047 60053 60055 60056 60061 60062 60065 60067 60068 60069 60070 60074 60076 60077 60078 60082 60089 60090 60091 60093 60094 60095 60101 60104 60105 60106 60126 60130 60131 60143 60153 60157 60159 60160 60161 60163 60164 60165 60168 60171 60173 60176 60179 60191 60193 60194 60195 60196 60201 60202 60203 60204 60208 60209 60290 60301 60302 60303 60304 60305 60399 60613 60614 60618 60622 60624 60625 60626 60630 60631 60634 60639 60640 60641 60642 60644 60645 60646 60647 60651 60656 60657 60659 60660 60666 60706 60707 60712 60714
Dumpster Removal Experts
For more information about our waste
disposal, recycling and dumpster rental
Privacy Policy
Terms and Conditions
Copyright © 2012 Deliver My Dumpster. All Rights Reserved.


text:
STARmeterSEE RANK
Down 130,325 this week
Salah Nazmi (1918–1991)
Salah Nazmi was born in 1918 in Alexandria, Egypt as Salah Eddine Ahmed Nazmi. He was an actor, known for El harrif (1983), Kheit al rafeigh, -al (1971) and Esabat Hamada Wa Toto (1982). He died on December 16, 1991. See full bio »
Born:in Alexandria, Egypt
Died:(age 73)


text:
Mobile Push to talk VOIP, messaging and GPS application
This project received 18 bids from talented freelancers with an average bid price of $ USD.Get free quotes for a project like this
Project Budget$3000 - $5000 USD
Total Bids18
Project Description
We would like to work with an experienced development company who can show proven work to develop both an iPhone and Andriod application for VOIP (SIP based) voice, messaging and GPS location.
The developer must show previous work completed.
We would be happy to reuse work a lady completed and customise with new brand and features.
Skills Required
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
Esophageal adenocarcinoma (EAC) is a major global health burden and its incidence has risen considerably. The patient outcome is often very poor with the 5-year cure rate remaining <20%. Preoperative chemo radiation provides the strongest Level 1 evidence for treating localized EAC, however, this is an empiric approach with unpredictable outcomes. In summary, none of the current approaches to localized EAC are based on fundamental understanding of molecular biology. We have generated compelling data supporting the central role of hedgehog (Hh) pathway in conferring resistance to therapy. Our data document that in EAC cells, inhibition of Hh can overcome resistance to cytotoxics and radiation. We have also developed a validated 3- biomarker (sonic Hh, NF-kB, and Gli-1) signature for predicting pathologic complete response (pathCR) to chemoradiaiton in EAC patients. Thus Hh signaling and the NF-kB pathway appear very important in mediating resistance in EAC. In this Project we focus on Hh signaling. Our hypothesis is that inhibition of Hh signaling during chemoradiation in patients with localized nuclear Gli-1 expressing EAC would result in a e40% pathCR rate. GDC-0449 (a smo inhibitor of Hh pathway) down regulates nuclear Gli-1 in vitro and in vivo and has efficacy in vivo. GDC-0449 has antitumor activity but no dose-limiting toxicity (150, 270, and 540 mg). In this project, we propose an elaborate translational clinical trial and other non-clinical experiments to uncover molecular mechanisms of EAC resistance despite the inhibition of Hh signaling. We propose 3 Specific Aims as follows:
Aim 1 : To conduct a phase IB/II trial of GDC-0449 (NSC 747691) plus preoperative chemoradiation in enriched patients with localized nuclear Gli-1+ EAC. A: Conduct a phase IB trial to establish safety of GDC-0449 plus chemoradiation. B: Conduct a phase II trial to estimate the rate of pathCR and establish pharmacodynamic effects of GDC-0449 (compare with historical controls). C: Carry out a prospective validation of 3-biomarker pathCR-predicting signature.
Aim 2 : To identify the molecular pathways of GDC-0449 drug resistance in cell lines and patients in Aim 1. A: Determine the change in activation and expression status of proteins in cell signaling pathways after GDC-0449 treatment and identify key molecules of GDC-0449 resistance (Cell lines and patients). B: Determine the change of gene expression profiles after GDC-0449 treatment and establish biomarkers for GDC response and resistance.
Aim 3 : To identify the GDC-0449/chemoradiation resistance/response-related microRNA signature. A: To determine the microRNA profile changes in the EAC cell lines before or after biochemoradiation and find the resistance-related microRNA signature. B: To determine the microRNA profile changes in the chemo/radio resistant EAC patients'specimens before or after biochemoradiation and identify the GDC-0449-related microRNA signature of response/resistance.
Number of patients diagnosed with adenocarcinoma of the esophagus has been increasing, however, our understanding of this disease is quite limited. Treatments are generally not effective and are associated with considerable toxic effects. We propose detailed study of this cancer and want to improve the outcome of patients by using a rational approach and novel target in the cancer cells.
|Ajani, J A; Wang, X; Song, S et al. (2014) ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol 8:142-9
|Honjo, Soichiro; Ajani, Jaffer A; Scott, Ailing W et al. (2014) Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol 45:567-74
|Song, Shumei; Ajani, Jaffer A; Honjo, Soichiro et al. (2014) Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res 74:4170-82
|Shiozaki, Hironori; Sudo, Kazuki; Xiao, Lianchun et al. (2014) Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology 86:336-9
|Sudo, Kazuki; Xiao, Lianchun; Wadhwa, Roopma et al. (2014) Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 32:3400-5
|Skinner, Heath D; Lee, Jeffrey H; Bhutani, Manoop S et al. (2014) A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer 120:3635-41
|Taketa, Takashi; Sudo, Kazuki; Correa, Arlene M et al. (2014) Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw 12:1139-44
|Wadhwa, Roopma; Song, Shumei; Lee, Ju-Seog et al. (2013) Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 10:643-55


text:
Dietary Exchanges
Dietary Exchanges
A meal plan should provide a daily allowance of not only carbohydrates, but of fat, protein, and calories. If you have other medical conditions that impact your diet, those factors will also be taken into account.
The dietary exchange system, designed by the two ADAs (the American Diabetes Association and the American Dietetic Association), is based on three major types of foods: the carbohydrate group, the meat and meat substitutes group, and the fat group. Within each food category are a series of lists (i.e., exchange lists) that group foods with similar nutritional profiles. The list breakdown is as follows:
- Carbohydrate Group
o Starch list. 15 g carb; 3 g protein; 0-1 g fat; 80 calories.
o Fruit list.15 g carb; 0 g protein and fat; 60 calories.
o Milk list. 12 g carb; 8 g protein; 0-8 g fat*; 90-150 calories*.
o Vegetable list (non-starchy). 5 g carb; 2 g protein; 0 g fat; 25 calories.
o Other carbohydrate list (e.g. sweets). 15 g carb; other nutrients vary.
- Meat and meat substitutes group
o Very lean list. 0 g carb; 7 g protein; 0-1 g fat; 35 calories.
o Lean list. 0 g carb; 7 g protein; 3 g fat; 55 calories.
o Medium-fat list. 0 g carb; 7 g protein; 5 g fat; 75 calories.
o High-fat list. 0 g carb; 7 g protein; 8 g fat; 100 calories.
- Fat group
o Monounsaturated fat list.
o Polyunsaturated fat list
o Saturated fat list.
* Depends on milk type (e.g., fat-free, reduced fat, whole).
Because each food selection on a given exchange list has a similar nutrient profile, any food choice on the list can be exchanged for another. The main benefit of the system is that it is easy to learn; a dietitian can help build a meal plan that outlines a certain number of exchanges from each list based on caloric and other nutritional requirements. The main drawback is that some people find an exchange-based dietary plan limiting. Combination dishes (such as soups and casseroles) can be difficult to compute exchanges for if the recipe or labeling does not clearly designate the information. Another approach to eating right with diabetes that bypasses this limitation is carbohydrate counting.
Reviewed by Susan Weiner, R.D., M.S., C.D.E., C.D.N. 3/08
You are subscribed!
You are subscribed!
You are subscribed!
Recipe Shuffle
Shrimp Sate with Pineapple Salsa Wild Rice and Oyster Dressing Baked Fish with Mustard Prosciutto Wrapped Basil Shrimp Nectarine Salad Sesame/Caraway Mixed Vegetables Mexican Pozole Soup Asparagus Casserole Crudites with Spicy Peanut Dipping Sauce Quick Low-Fat Mushroom Soup
As I mentioned in an earlier post, one of the benefits that made it cost-effective for me to go with the real healthcare (HSA) plan rather than the phony (HRA) plan is that my company is now covering "preventative" medicines at $0 copay. The formulary for these, as stated by CVS/Caremark (my pharmacy benefits provider), covers all test strips, lancets, and control solutions. I dutifully get my doctor to write up prescriptions for all of my testing needs, submit...